With Regeneron's covid antiviral "antibiotic" havi
Post# of 72440
(Total Views: 1033)
Posted On: 12/19/2021 12:10:14 AM
With Regeneron's covid antiviral "antibiotic" having limited effect against the omicron variant and sotrovimab being in limited supply, my bet is the NIH would welcome another antiviral. Especially one with possible pancorona virus effects.
https://www.yahoo.com/news/omicron-variant-th...58773.html
https://www.reuters.com/business/healthcare-p...021-12-14/
https://www.globenewswire.com/en/news-release...eutic.html
Pfizer's new oral antiviral effects may begin to wane 5 days post the onset of symptoms.
https://www.pfizer.com/news/press-release/pre...dy-results
IMO Brilacidin's chances to be included in the NIH ACTIV trial have improved.
https://www.ipharminc.com/press-release/2021/...-19-trials
How many mutants will follow delta and omicron? What medications will be resistant to the new Covid variants?
GLTA,
Farrell
https://www.yahoo.com/news/omicron-variant-th...58773.html
https://www.reuters.com/business/healthcare-p...021-12-14/
https://www.globenewswire.com/en/news-release...eutic.html
Pfizer's new oral antiviral effects may begin to wane 5 days post the onset of symptoms.
https://www.pfizer.com/news/press-release/pre...dy-results
IMO Brilacidin's chances to be included in the NIH ACTIV trial have improved.
https://www.ipharminc.com/press-release/2021/...-19-trials
How many mutants will follow delta and omicron? What medications will be resistant to the new Covid variants?
GLTA,
Farrell
(12)
(0)Innovation Pharmaceuticals Inc (IPIX) Stock Research Links
Scroll down for more posts ▼